NCT04479813 - Role of Sympathetic Activation in Ischemia Reperfusion Injury | Biotech Hunter

Enrollment

46

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

Central Sympathetic Nervous System Diseases

Interventions

DRUG

Moxonidine 0.2 MG

Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

OTHER

placebo

Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Trial Locations (1)

Unknown

Dobney Hypertension Centre, Perth